BC Cancer Protocol Summary for Topical Carmustine in Cutaneous T-cell Lymphoma

**Protocol Code**
LYCARTOP

**Tumour Group**
Lymphoma

**Contact Physician**
Dr. Vincent Ho

**ELIGIBILITY:**

- Histology: cutaneous T-cell lymphoma (mycosis fungoides)
- Used as an alternate to topical mechlorethamine (nitrogen mustard, LYMECHLOR).
  Note: carmustine does not cross react with other alkylating agents and can be used in patients allergic to mechlorethamine.

**TESTS:**

- Baseline (required before first treatment): CBC and diff, platelets
- For application to greater than 10% BSA: monthly CBC and diff, platelets x 1 year or as specified by Skin Lymphoma Team member
- For application to less than 10% BSA: q 3 monthly CBC and diff, platelets x 1 year or as specified by Skin Lymphoma Team member

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>carmustine</td>
<td>0.4% in white petrolatum</td>
<td>Apply daily to lesions as directed by Skin Lymphoma Team member</td>
</tr>
</tbody>
</table>

Treatment will continue daily until 1 year after remission or as specified by Skin Lymphoma Team member.
DOSE MODIFICATIONS:
1. Hematological:

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 1.2</td>
<td>or less than 75</td>
<td>variable</td>
</tr>
</tbody>
</table>

Contact your Skin Lymphoma Team member

PRECAUTIONS:
1. Cutaneous Reactions: Erythematous reactions may occur as early as 4 weeks after initiating treatment. Erythema, skin tenderness and telangiectasia may occur. If this occurs, stop applying the ointment to the affected areas until this resolves.
2. Drug Interactions: Because carmustine can be absorbed systemically from topical application, other drugs such as cimetidine, digoxin (LANOXIN®) and phenytoin (DILANTIN®) may interact with carmustine.

Call tumour group chair at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

REFERENCES: